Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
Priovant Therapeutics announced FDA approval of LISRAYA™ (brepocitinib), a first-in-class TYK2/JAK1 inhibitor, for the treatment of adults with dermatomyositis, a rare systemic autoimmune disease. The approval follows positive Phase 3 VALOR trial results demonstrating significant improvements in disease activity and steroid-sparing benefits. LISRAY…